Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.

Andrea Dueregger, Bernd Schöpf, Theresa Eder, Julia Höfer, Erich Gnaiger, Astrid Aufinger, Lukas Kenner, Bernhard Perktold, Reinhold Ramoner, Helmut Klocker, Iris E Eder

Journal: PloS one 2016;10(8):e0135704

PMID: 26285134

Abstract

Tumor cells adapt via metabolic reprogramming to meet elevated energy demands due to continuous proliferation, for example by switching to alternative energy sources. Nutrients such as glucose, fatty acids, ketone bodies and amino acids may be utilized as preferred substrates to fulfill increased energy requirements. In this study we investigated the metabolic characteristics of benign and cancer cells of the prostate with respect to their utilization of medium chain (MCTs) and long chain triglycerides (LCTs) under standard and glucose-starved culture conditions by assessing cell viability, glycolytic activity, mitochondrial respiration, the expression of genes encoding key metabolic enzymes as well as mitochondrial mass and mtDNA content. We report that BE prostate cells (RWPE-1) have a higher competence to utilize fatty acids as energy source than PCa cells (LNCaP, ABL, PC3) as shown not only by increased cell viability upon fatty acid supplementation but also by an increased ß-oxidation of fatty acids, although the base-line respiration was 2-fold higher in prostate cancer cells. Moreover, BE RWPE-1 cells were found to compensate for glucose starvation in the presence of fatty acids. Of notice, these findings were confirmed in vivo by showing that PCa tissue has a lower capacity in oxidizing fatty acids than benign prostate. Collectively, these metabolic differences between benign and prostate cancer cells and especially their differential utilization of fatty acids could be exploited to establish novel diagnostic and therapeutic strategies.

Address: Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria; Oncotyrol GmbH, Center for Personalized Medicine, Innsbruck, Austria.; Oncotyrol GmbH, Center for Personalized Medicine, Innsbruck, Austria; Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria; Oroboros Instruments, High-Resolution Respirometry, Innsbruck, Austria.; Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.; Oroboros Instruments, High-Resolution Respirometry, Innsbruck, Austria; Department of General and Transplant Surgery, D. Swarovski Research Laboratory, Medical University of Innsbruck, Innrain 66/6, A-6020, Innsbruck, Austria.; Clinical Institute for Pathology, Medical University Vienna, Vienna, Austria.; Diätologie, FHG-Zentrum Für Gesundheitsberufe Tirol GmbH, Innsbruck, Austria.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.